1. Ivonin A.G., Pimenov E.V., Oborin V.A., Devrishov D.A., Kopylov S.N. Napravlennyi transport lekarstvennykh preparatov: sovremennoe sostoyanie voprosa i perspektivy. Izvestiya Komi nauchnogo tsentra UrO RAN. 2012; 9: 46-55.
2. Berezov T.T., Yaglova N.V., Dmitrieva T.B., Zhirkov Yu.A., Chekhonin V.P. Napravlennyi transport lekarstvennykh sredstv s pomoshch'yu liposom. Vestnik Rossiiskoi akademii meditsinskikh nauk. 2004; 5: 42-47.
3. Sanzhakov M.A., Ignatov D.V., Kostryukova L.V., Druzhilovskaya O.S., Medvedeva N.V., Prozorovskii V.N., Ipatova O.M. Izuchenie svoistv lekarstvennykh kompozitsii doksorubitsina v sostave kolloidnykh nanochastits s adresnym fragmentom v eksperimentakh in vivo. Biomeditsinskaya khimiya. 2016; 62 (2): 150-153.
4. Yabbarov N.G., Posypanova G.A., Vorontsov E.A., Popova O.N., Severin E.S. Napravlennyi transport doksorubitsina: sistema dostavki na osnove pamam dendrimerov. Biokhimiya. 2013; 78 (8): 1128-1140.
5. Pyataev N.A., Gurevich K.G., Zaborovskii A.V., Kokorev A.V., Minaeva O.V., Zyrnyaeva N.A., Kladiev A.A., Bychkovskii P.P., Revmtovich M.Yu. Effektivnost' kombinatsii svobodnoi i polimer- svyazannoi form prospidina s doksorubitsinom u krys s astsidnoi gepatomoi Zaidela. Khimiko-farmatsevticheskii zhurnal. 2014; 48 (11): 96-100.
6. Zyrnyaeva N.N., Minaeva O.V., Brodovskaya E.P., Stolyarov G.S., Firstov S.A., Zaborovskii A.V., Shemsutdinova E.E. Sravnitel'naya effektivnost' nekotorykh metodov targetnoi khimioterapii pri eksperimental'noi kartsinome rs-1 u krys. Sovremennye problemy nauki i obrazovaniya. 2015; 6 0: 76.
7. Gorbik P.P., Petranovskaya A.L., Turelik M.P., Abramov N.V., TuranskayaS.P., Pilipchuk E.V., Chekhun V.F., Luk'yanova N.Yu., Shpak A.P., Korduban A.M Problema napravlennogo transporta lekarstvennykh preparatov: sostoyanie i perspektivy. Khіmіya, fіzika ta tekhnologіya poverkhnі. 2011; 2 (4): 461-469.
8. Pyataev N.A., Gurevich K.G., Skopin P.I., Minaeva O.V. Targetnaya farmakoterapiya v onkologii. Meditsina kriticheskikh sostoyanii. 2010; 5: 3-14.
9. Gervas P.A., Litvyakov N.V., Popova N.O., Dobrodeev A.Yu., Tarasova A.S., Yumov E.L., Ivanova F.G., Cheremisina O.V., Afanas'ev S.G., Gol'dberg V.E., Cherdyntseva N.V. Problemy i perspektivy sovershenstvovaniya molekulyarno-geneticheskoi diagnostiki dlya naznacheniya targetnykh preparatov v onkologii. Sibirskii onkologicheskii zhurnal. 2014; 2: 46-55.
10. Ulashchik V.S. Sovremennye tekhnologii napravlennogo transporta lekarstvennykh veshchestv. Zdravookhranenie (Minsk). 2015; 4: 12-19.
11. Zaborovskii A.V., Tararina L.A., Mulyar A.G., Pyataev N.A., Gurevich K.G. Razrabotka novykh protivoopukholevykh preparatov na osnove polimernykh nanochastits dlya terapii neoplazii. Sistemnyi analiz i upravlenie v biomeditsinskikh sistemakh. 2016; 15 (3): 401-403.
12. Pyataev N.A., Gurevich K.G., Belyaev A.N., Minaeva O.V. Farmakokinetika i farmakodinamika antibakterial'nykh preparatov pri napravlennom transporte u patsientov s tyazheloi pnevmoniei. Meditsina kriticheskikh sostoyanii. 2008; 3 (3): 11-17.
13. Gurevich K.G., Romanov M.D., Belyaev A.N., Pyataev N.A., Minaeva O.V. Sravnitel'naya farmakokinetika eritromitsina pri napravlennom kletochno-assotsiirovannom transporte i vnutrivennom vvedenii u patsientov s pnevmoniei. Vestnik MGU. 2006; 2: 109-114.
14. Varfolomeev S.D., Gurevich K.G. Biokinetika. Prakticheskii kurs. M., 1999; 720 s.
15. Pérez-Blanco J.S., Santos-Buelga D., Fernández de Gatta M.D., Hernández-Rivas J.M., Martín A., García M.J. Population pharmacokinetics of doxorubicin and doxorubicinol in patients diagnosed with nonHodgkin’s lymphoma. Br J Clin Pharmacol. 2016 Dec; 82 (6): 1517-1527. https://doi.org/10.1111/bcp.13070.
16. Gong C., Qian L., Yang H., Ji L.L., Wei H., Zhou W.B., Qi C., Wang C.H. Hepatotoxicity and pharmacokinetics of cisplatin in combination therapy with a traditional Chinese medicine compound of Zengmian Yiliu granules in ICR mice and SKOV-3-bearing nude mice. BMC Complement Altern Med. 2015 Aug 18; 15: 283. https://doi.org/10.1186/ s12906-015-0799-9.
17. Li J., Chen R., Ji M., Zou S.L., Zhu L.N. Cisplatin-based chronotherapy for advanced non-small cell lung cancer patients: a randomized controlled study and its pharmacokinetics analysis. Cancer Chemother Pharmacol. 2015 Sep; 76 (3): 651-5. https://doi.org/10.1007/s00280-015-2804
18. Balis F.M., Holcenberg J.S., Bleyer W.A. Clin Pharmacokinet. 1983 May-Jun; 8 (3): 202-32.
19. Balis F.M., Holcenberg J.S., Bleyer W.A. Clinical pharmacokinetics of commonly used anticancer drugs. Clinical pharmacokinetics. 1983; 8 (3): 202-232.
20. Canal P., Chatelut E., Guichard S. Practical treatment guide for dose individualisation in cancer chemotherapy. Drugs. 1998 Dec; 56 (6): 1019-38.
21. Crombag M.R., Joerger M., Thürlimann B., Schellens J.H., Beijnen J.H., Huitema A.D. Pharmacokinetics of Selected Anticancer Drugs in Elderly Cancer Patients: Focus on Breast Cancer. Cancers (Basel). 2016 Jan 2; 8 (1). pii: E6. https://doi.org/10.3390/cancers8010006.
22. Kerr D.J., Haller D.G., C.J.H. van de Velde, Baumann M. Oxfrord textbook of oncology. Oxford: OUP, 2016; 975 p.
23. Korman D.B. Misheni i mekhanizmy deistviya protivoopukholevykh preparatov. M., 2014; 336 s.
24. Liang C., Xu L., Song G., Liu Z. Emerging nanomedicine approaches fighting tumor metastasis: animal models, metastasis-targeted drug delivery, phototerapy, andimmunoterapy. Chem Soc Rev. 2016 Nov 7; 45 (22): 6250-6269.
25. Moskaleva E.Yu., Semochkina Yu.P., Rodina A.V., Severin S.E. Analogi somatostatina v kachestve vektornykh molekul dlya sozdaniya targetnykh protivoopukholevykh preparatov. Molekulyarnaya meditsina. 2014; 1: 3-12.
26. Gel'perina S.E., Smirnova Z.S., Skidan I.N., Kroiter I. Issledovanie nanosomal'noi lekarstvennoi formy doksorubitsina. Rossiiskii bioterapevticheskii zhurnal. 2004; 3 (3): 56-64.